EGFR is overexpressed in 62% of cases of NSCLC and patients with this mutation have high response rates to treatments with tyrosine kinase inhibitors; therefore, this has become the standard treatment for patients with this mutation (8). This evidence concerns the gene EGFR and non-small cell lung carcinoma.